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Development ofinduced pluripotent stem cells (iPSCs)usingforced expression of speciﬁc sets of transcription factors has changed
the ﬁeld of stem cell research extensively. Two important limitations for research application of embryonic stem cells (ESCs),
namely, ethical and immunological issues, can be circumvented using iPSCs. Since the development of ﬁrst iPSCs, tremendous
eﬀorthasbeendirectedtothedevelopmentofmethodstoincreasetheeﬃciency oftheprocessandtoreducetheextentofgenomic
modiﬁcations associated with the reprogramming procedure. The established lineage-speciﬁc diﬀerentiation protocols developed
for ESCs are being applied to iPSCs, as they have great potential in regenerative medicine for cell therapy, disease modeling either
for drug development or for fundamental science, and, last but not least, toxicity testing. This paper reviews eﬀorts aimed at
practical development of iPSC diﬀerentiation to neural/cardiac lineages and further the use of these iPSCs-derived cells for drug
development and toxicity testing.
1.Introduction
Thehistoryofinducedpluripotency/cellularreprogramming
dates back to the 1950s when Briggs and King developed a
technique of nuclear transfer (NT) to test the developmental
potential of late-stage blastula cells following transfer into
enucleated Xenopus oocytes [1]. Later experiments [2, 3]
with the transfer of nuclei of diﬀerentiated cells into the
amphibian oocyte lead to the production of live oﬀspring
suggesting genetic/epigenetic reprogramming of the diﬀer-
entiated cells to the totipotent/pluripotent state. In mam-
malians, the ﬁrst adult-cell-derived animal, Dolly the sheep,
was produced using SCNT only in 1997 [4], strengthening
the concept of epigenetic reprogramming of the diﬀer-
entiated mammalian cells to totipotent/pluripotent state
mediated by the ooplasm. Several reports later proved that
the oocyte contains certain factors which are responsible for
the reprogramming of the transferred genome [5, 6].
Moreover the fusion of the somatic cells with pluripotent
stem cells such as embryonal carcinoma cells (ECCs) derived
from teratocarcinoma [7, 8] was able to induce pluripotency
in the somatic cells [9]. This suggests that the pluripotent
cells contain certain factors which are responsible for the
conversion of the somatic cells into the pluripotent state.
Embryonicstemcells(ESCs)derivedfromtheinnercellmass
ofmouse[10]andsubsequentlyfromhumanblastocysts[11]
are considered pluripotent. Mouse ESCs are able to con-
tribute to all kinds of tissues of the live oﬀspring after injec-
tion into the blastocysts. The pluripotency of human and
m o u s eE S C sh a v eb e e ns h o wni nvi v ob yt e r a t o m af o r m a t i o n
and in vitro by embryoid body diﬀerentiation assays to form
tissue of the three germ layers (endoderm, ectoderm, and
mesoderm) [12]. The expression of key transcription factors
such as OCT4, SOX2, and NANOG is mandatory to keep
these cells self-renewing and pluripotent. Fusion of ESCs2 Stem Cells International
with somatic cells has led to the conversion of somatic cells
from diﬀerentiated to pluripotent state.
The conclusion from the above observations is that the
pluripotent cells have certain regulatory pathways involv-
ing powerful transcription factors which are suﬃcient to
revert the somatic cells to a pluripotent state. Screening of
24 diﬀerent transcription factors by the Yamanaka group
[13] surprisingly demonstrated that generation of induced
pluripotent stem cells (iPSCs) required a combination of
only four transcription factors: OCT4, SOX2, KLF4, and c-
Myc (OSKM) [13]. These iPSCs were almost identical to
ESCsatthemolecularaswellasmorphologicallevel.Genera-
tion of iPSCs has fundamentally changed stem cell research
considerably. In the case of iPSCs derived from somatic cells,
theethicalissuesandimmunocompatibilityproblemsarising
from use of ESCs for cell therapy can be avoided. Mouse and
human iPSCs can therefore be used to study the early devel-
opmental process, disease mechanisms, cell therapy, drug
discovery, and toxicity testing assays. Methods developed to
produce the iPSCs with no/less genetic modiﬁcations are
under examination for robustness and ease of use.
2. Methods to ProduceiPSCs
Since the description of the ﬁrst iPSCs from mouse [13]a n d
human[14],severaloptimizedmethodshavebeendeveloped
to produce iPSCs from various tissues and species [15–20].
The c-Myc from the original OSKM factors was thought
being responsible for tumorigenicity [21] and thus aﬀecting
the potential clinical use of the cells. Consequently, eﬀorts
were made to screen more transcription factors, and the
iPSCs were produced using a set of transcription factors
OCT4, SOX2, NANOG, and LIN28 suggesting alternative
factors aﬀecting the pathways needed for reprogramming
[22–24]. iPSCs can also be generated with fewer transcrip-
tion factors [25]. Initially the technology involved the use
of retroviral or lentiviral vectors for the transduction of the
reprogramming factors. This technique leads to the integra-
tion of the viral vectors in the genome causing insertional
mutations, and these cells are not likely to be acceptable for
the clinical purposes. This problem was partially overcome
by the use of a single polycistronic lentiviral vector carrying
all OSKM factors reducing the number of insertions in the
genomes [26, 27]. Furthermore, the use of nonintegrative
viral vectors has also been suggested [28].
Options towards delivering the reprogramming factors
with less or no genetic modiﬁcation include the use of LoxP
sites and Cre-induced excision of the transgenes—this has
been achieved successfully—while in case of transposon-
mediated gene transfer the suggested excision by transposase
of the integrated vector sequences has never been published
[29–31].
Protein transduction can completely replace the need for
gene delivery for the generation of iPSCs. The conjugation of
proteins with the short peptides responsible for cell penetra-
tion can be used for delivery of the proteins into the cells.
Mouse and human iPSCs were generated with this approach
using puriﬁed polyarginine-tagged OCT4, SOX2, KLF4, and
c-MYC proteins [32–34]. Yamanaka factors have also been
introducedbyanmRNA-transfectionmethod,Althoughthis
approach is reported to be more eﬃcient and is not based
on integration into the host genome, there is still a very low
but not negligible risk of genetic alteration given that the
exogenous substance introduced into the cells is nucleic acid
[35].
Though until recently the protein iPSCs was considered
as the best approach, the use of microRNAs (miRNAs) with
orwithouttranscriptionfactorshasbeenshowntobeaneﬃ-
cient method to generate these cells [36, 37]. The generation
of iPSCs using only miRNAs without any transcription fac-
tors has created an interesting puzzle concerning the mech-
anisms of reprogramming [37]. Notwithstanding the enig-
matic mechanism behind the miRNA-mediated reprogram-
ming, presently this method oﬀers the highest published
yieldofreprogrammedcellsanddoesnotmodifythegenome
of the cells—qualifying miRNA-reprogrammed cells for
potential clinical applications. Nevertheless, further evalua-
tion and conﬁrmations by independent teams will be needed
to demonstrate the superiority of any given method—
although all of them become commercially available (and
patent protected) within months of their ﬁrst publication,
often without independent validation.
3. ESCsandiPSCsinDrugDiscovery and
Toxicity Testing
Developing reliable systems to study drug toxicity is a major
challenge for developing new and safe drugs for the treat-
ment of humans. Currently, toxicological testing is based on
the established immortal cancer cells lines containing chro-
mosomal abnormalities, primary explanted somatic cells,
and laboratory animals. Immortalized cell lines, showing
severalfeaturesreminiscentofcancer,mimicneitherthenor-
mal physiological status nor the diseased state of the organ-
ism in vivo. The heterogeneity of primary explant cultures
leads to inconsistent results and low reproducibility in toxic-
ity testing. Using live animal models for toxicity testing may
not mimic the human physiology, can raise ethical/animal
welfare concerns, and is rather expensive. Research on ESCs
and iPSCs promises to enhance drug discovery and develop-
ment by providing simple, reproducible, and cost-eﬀective
tools for toxicity testing of drugs under development and,
on the other hand, for studying the disease mechanisms and
pathways [38–40]. Modeling human disease in standardised
cell culture and the opportunity for high throughput drug
screening are potential advantages of using iPSCs [38].
Patient-speciﬁc iPSCs could improve the eﬃciency of drug
discovery by helping the identiﬁcation of drugs eﬀective in
speciﬁc patient populations.
T h eE S C s ,a n dt os o m ee x t e n ti P S C s ,d i ﬀerentiated either
into cardiac or into neural cell types have been used widely
for drug discovery and toxicity testing. This application is
the most advanced and practical use of pluripotent cells;
however, the acceptance of major pharmaceutical companies
to adopt new approaches and replace the well-established
andFDA-approvedtestmethodsisaratherslowprocess[40–
43]. Consequently, disease models developed from iPSCs
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reachedclinical trials. Someexperiments andongoing eﬀorts
will be the focus of the remainder of this paper.
4.ESC-andiPSC-DerivedNeuronsin
Drug Discovery
Neurodegenerative diseases including Parkinson’s disease
(PD), Alzheimer’s disease (AD), Huntington’s disease (HD),
andamyotrophiclateralsclerosis(ALS)constituteanincreas-
ing burden for society. The mechanisms of neurological
disorders like AD and PD is not well known due to the
limited accessibility of the diseased tissue. Several iPSC lines
were derived from spinal muscular atrophy (SMA) [44],
schizophrenia [45], familial dysautonomia (FD) [46], and
Friedreichs ataxia (FA) patients [47] to study the disease
progression. The diﬀerentiation potential of ESCs and iPSCs
into functional neurons and glia is known, and the speciﬁc
culture conditions needed for the diﬀerentiation of ESCs and
iPSCs into neural lineage for optimization of drug discovery
modelsaremoreorlessestablishedeventhoughneedfurther
reﬁnement.
The establishment of in vitro models of ALS by dif-
ferentiation of ESCs into motor neurons was one of the
pioneering examples [48–50] of neurological disease model-
ing. Transgenic mice carrying human superoxide dismutase
mutation (G93A) responsible for ALS were used for ESC
isolation. The major observation made by this study was
the more rapid death of G93A-positive motor neurons than
their wild-type counterparts. Moreover, the astrocytes in
the G93A-positive cultures were involved in the secretion
of toxic factors causing selective and increased death of
motor neurons without having an eﬀect on interneurons.
Human ESC-derived motor neurons were also killed by the
mutant mouse astrocyte-conditioned medium [49, 51]. This
work has demonstrated the potential for successful disease
modeling using ESC-derived neuronal and astroglial cells.
A group of neurodevelopmental defect related autism
spectrum disorders (ASD) have also been studied using
iPSCs [52], including the Rett syndrome caused by the X-
chromosomelinkedMeCP-2mutation.Thismutationcauses
impaired neural development after one year of age and
the aﬀected individual shows symptoms similar to other
ASDs. iPSCs generated from the aﬀected individuals were
diﬀerentiated into GABAergic inhibitory and glutamatergic
excitatory neurons. Interestingly, erased X-inactivation of
the MeCP-2 during reprogramming was reestablished in the
diﬀerentiated neurons, an observation that highlights the
great potential that exists in disease modeling by pluripotent
cells, and also the need of producing the congruent cell-type
by diﬀerentiation from pluripotent cells for the purpose of
disease modeling. After 2 months—in culture no signiﬁcant
eﬀect on survival of the MeCP-2 neurons was observed.
However, the number of glutamatergic synapses decreased
signiﬁcantly as observed in the Rett syndrome. Interestingly,
treatment of these neuronal cultures with the insulin-
like growth factor 1 (IGF-1) has shown an increase in
the number of synapses, pinpointing the fact that rescue
experiments can successfully be designed based on cultures
of neurons harboring a disease-speciﬁc mutation. Overall,
this demonstrates the ability of patient speciﬁc iPSCs in
helping understand complex neurodegenerative diseases and
to serve as a model for drug discovery.
Another major neurological disorder PD, that aﬀects a
subset of midbrain dopaminergic neurons, is a sporadic and
late-onset disease. Out of several identiﬁed mutations the
most common PD associated mutation is in Leucine-rich
repeat kinase-2 (LRKK2). iPSCs generated from patients car-
rying a LRKK2 mutation were diﬀerentiated down the neu-
ronal lineage and physiologically active dopaminergic neu-
rons were produced [53]. The comparative analysis of gene
expression proﬁle by microarray has shown that neurons
produced from the patient iPSCs had higher expression of
oxidativestressgenes,comparedtothecontrolpatientiPSCs.
Moreover,theproteinα-synuclein,responsibleforformation
of characteristic aggregates in PD was highly expressed [54].
These neurons were found to be susceptible to hydrogen
peroxide and 6-hydroxydopamine like stressors. This exper-
iment demonstrated that the patient speciﬁc iPSC-derived
neurons can be used for neurological disease modeling.
Recently, FD, a genetic disease, caused by mutation in
IκB kinase complex-associated protein (IKBKAP) was stud-
ied by Lee et al., [46]. The disease leads to the death of neural
crest derived neurons in sensory and autonomic ganglia.
iPSCs were generated from the aﬀected individual and
were subjected to neuronal diﬀerentiation. The neural crest
precursors derived from these iPSCs showed low level of
IKBKAP protein as well as defective migration and neuronal
diﬀerentiation. The treatment of these cultures with kinetin,
a plant hormone has resulted in relatively strong corrective
eﬀects on the FD neuronal cells, demonstrating that the
iPSC-based drug discovery approach has good predictive
value—although the full clinical proof-of-concept is still far
away.
Thus, the patient-speciﬁc iPSCs oﬀer a unique opportu-
nity for studying and modeling the eﬀects of speciﬁc gene
defects on human neuronal development in vitro and for
testing small molecules or other potential therapies for the
relevant genetic disorders of the nervous system.
5.ESCandiPSC-DerivedCardiomyocytesin
Drug Discovery
Cardiovascular disease is considered as one of the major and
leading cause of death. Since adult cardiomyocytes have a
limited regenerative capacity, their loss permanently com-
promises myocardial contractile function leading to loss of
cardiac function and heart failure. Eﬀorts are being made to
developdiﬀerentwaysoftreatingcardiovasculardiseasesthat
involves not only perfecting the production of immunocom-
patible cardiomyocytes but also the establishment of more
sophisticated cellular drug discovery and test systems.
Rodentmodelsfailtomimicthebasicphysiologicalfunc-
tions of heart due to their having a much faster heart beat
thanhuman;thustheymakeunreliableanimalmodelstotest
the drugs for arrhythmias in human. Generation of iPSCs
from patients suﬀering congenital heart disease and their
diﬀerentiation into cardiomyocytes has been predicted to
serve as a model system to study disease pathogenesis and4 Stem Cells International
for drug discovery [55]. ESC- and iPSC-derived functional
cardiomycytes can potentially improve the eﬃciency of the
drug discovery and screening process [56–58]. Despite the
immature sarcomeric and myoﬁbrillar organization, the
ultrastructuralandmorphologicalsimilaritiesbetweenthein
vitroderivedcardiomyocytesandadultheartcardiomyocytes
make them the better choice model for drug discovery [58–
61]. Given that pluripotent cells can be diﬀerentiated into
cardiac cells that form a functional syncytium in vitro within
which action potential propagation is synchronized, previ-
ously unavailable models can be engineered for studying the
eﬀect of potential cardioactive drugs in the electric conduc-
tion in human cardiac tissue [62]. To build such models,
whichmightsubstituteforwholeanimalexperiments,diﬀer-
entiated cells have to be grown on the surface of multielec-
trode arrays (MEAs) [63]. The advantages of using in vitro
diﬀerentiated cardiomycytes include their ability to keep
the contractile function thereby providing the homogenous
cell culture for screening which ultimately contributes to
improvedhigh-throughputdrugdiscoveryprocess.ESCsand
iPSCs diﬀerentiated in vitro into cardiomyocytes are being
used by pharmaceutical companies to screen compounds
involved in several biological processes.
6.ESCsandiPSC-DerivedNeuronsin
Toxicity Testing
Toxic eﬀects of chemical compounds, environmental chan-
ges, and naturally occurring substances can lead to neuro-
toxicity which, in turn, leads to temporary or permanent
harm to the central or peripheral nervous system. In case
of excitotoxicity, a speciﬁc form of neurotoxicity, excessive
stimulation of the neurons occurs due to spinal cord injury,
stroke, or traumatic brain injury during which neurotrans-
mitters like glutamate and similar substances are responsible
for the damage and death of nerve cells. Environmental
toxicantsorpharmaceuticalagentscaninﬂuencesuchexcito-
toxic processes and can exaggerate their deleterious eﬀect.
Therefore, it is of utmost importance to develop more pre-
dictive cell-based models and powerful screening tools for
assessing the neurotoxicity of chemical compounds, drug
candidates, and environmental agents. Human neurons
derived from ESCs and iPSCs can be attractive models to
study the neurotoxicity. The ESC- and iPSC-derived neurons
exhibit functionality and behavior of mature neurons and
are available in large quantities. It is possible to develop
live cell assays that allow characterization of neurons and
neuronal networks for health and extent of the connectivity.
The neurotoxicity test models will allow for studying on one
hand the adverse eﬀect of drug candidates on neuronal cells
and on the other hand the general neurotoxicity in assays
that are well suited for screening of lead compounds and
potentially important for reducing animal experimentation
and the cost of preclinical development.
One variable that can be used in neurotoxicity tests and
can be easily turned into an assay endpoint is the amount
and changes of intracellular calcium. Several toxicants have
already been shown to have an eﬀect on intracellular calcium
homeostasis, which is a reliable indicator of neuronal health
and undisturbed function. Developing a system to visualize
intracellular calcium levels may shed light on similar toxic
eﬀects of previously uncharacterized substances. Currently,
cell lines such as PC12 are typically used for the analysis of
calcium signaling with the purpose of determining the com-
plex cellular changes triggered by environmental and phar-
macologic neurotoxicants [64]. However, scientiﬁc consen-
sus exists that this immortalized cell line does not recapit-
ulate the phenotypic features of neurons. Murine primary
neuronal cultures could be more adequate to address such
questions, but unfortunately the lifespan of such cultures is
typically 2-3 weeks, and their establishment requires sacri-
ﬁcing pregnant mice and dissecting their embryos. Several
studies have demonstrated the usefulness of calcium mea-
surements in assessing the toxicity of various compounds.
For instance, observing a decrease in the depolarization-
elicited calcium elevations that accompanies the release of
the speciﬁc neurotransmitter synthesized by a given neuron
can provide valuable information about the toxicity of an
uncharacterized compound. A similar approach has been
used to reveal the toxic eﬀects of hexabromocyclododecane
(HBCD),asubstancethatisnotbiodegradableunderaerobic
conditions and is very toxic to aquatic organisms [64]. Cal-
cium signals can also uncover excitotoxic eﬀects that previ-
ously uncharacterized substances might have. Excitotoxicity
is accompanied by an abnormally high level of neuronal
activation and a concomitant increase in intracellular cal-
cium,forinstance,hasbeenfoundtounderlietheneurotoxic
eﬀects tributyltin, a substance used as a heat stabilizer, agri-
cultural pesticide, and component of antifouling paints [65].
The relevance of calcium measurements for environmental
toxicity is exquisitely exempliﬁed by a study revealing that
neurotoxicantssuchasmanganese,lead,andbenzo(a)pyrene
(a product of incomplete combustion) alter the properties of
intracellular calcium waves [66].
Neurotoxicity screens using test systems (TSs) such as
two-dimensional neuronal culture with a deﬁned percentage
of neuronal subtypes or three-dimensional culture [67, 68]
diﬀerentiated from pluripotent cells are under development.
The TSs are studied by test methods (TMs) deﬁning a set
of variables (such as neurite length for example) to measure




eﬀects of a given compound at diﬀerent stages of neuronal
diﬀerentiation can also provide useful information about
speciﬁc developmental neurotoxicity [70].
7.ESCandiPSC-DerivedCardiomyocytesin
Toxicity Testing
Pluripotent stem cells can be spontaneously diﬀerentiated
into beating cardiomyocyte-like cells. The current cardiac
lineage diﬀerentiation system from pluripotent stem cells
includes use of spontaneous embryoid body (EB) formation
in suspension culture, coculture of pluripotent stem cells
with mouse endoderm-like cells (END-2 cells), and directed
diﬀerentiation towards cardiac lineage using deﬁned growthStem Cells International 5
factors (such as BMP-4 or activin) either in suspension or in
monolayer culture (REFs).
Cardiotoxicity can lead to the formation of reactive oxy-
gen species (ROS), apoptosis, altered contractibility, change
in cardiac rhythm, and altered cardiac gene expression,
whichcanbelifethreateningormayleadtolong-termaltera-
tionsofcardiovascularfunctions.Ofthe40%ofdrugfailures
during the clinical trials [71, 72], 19% drug withdrawal has
been observed due to cardiotoxicities—thus it is extremely
important to test the safety and eﬃciency of the drugs using
an appropriate model system [73]. Development of high-
throughput technologies (where more than, 100 molecules
can be tested) for drug screening, evaluation and toxicity
testing can help to identify the best compound, and improve
the eﬃciency of drug discovery, and save economic loss [71].
Inmanycardiotoxicitycases,adirectinteractionofdrugs
with speciﬁc ion channels expressed by the cardiomyocytes
leads to alteration in ion conduction through these speciﬁc
channels. Drug eﬀects on potassium currents could lead to
QT-prolongation, potentially fatal arrhythmias and some-
timescardiomusculardamagewithoutaﬀectingionchannels
[42, 74]. Cancer chemotherapies might cause cardiomyocyte
apoptosis and dysfunction; however, diﬀerent chemothera-
peutics might have diﬀerent toxicity mechanisms [75, 76].
In pharmaceutical industries, the cardiotoxicity test models
are based on cell lines, animal cardiomyocytes, and small/
large animal models [40, 41]. Failure of animal tissue model
systems to respond to the drugs in a similar manner as hu-
man tissue responds has motivated some of the pharma-
ceutical companies to use human ESCs and iPSCs derived
cardiomyocytes for the cardiotoxicity testing [40–42]; it is
expected that with time other companies will follow this
example.
Several protocols and strategies have been reported for
in vitro diﬀerentiation of cardiomyocytes from ESCs and
iPSCs.Thesecardiomyocytesarefunctionalin vitroandhave
respondedtothedrugsinsimilarwayasfetalcardiomyocytes
[77]. Usually, a subset of drugs with known and accepted
arrhythmogenic properties can be used to treat the ESC-
and iPSC-derived cardiomyocytes for functional character-
ization. Encouraging results have been obtained with the
use of electrophysiology for studying the response of the
ESC- and iPSC-derived cardiomyocytes to drug treatment.
However, these results have limitations due to the diﬀerent
experimental setup and number of drugs in each study.
Human pluripotent stem-cell-derived cardiomyocytes
have been used to study drug-induced QT interval pro-
longation [41, 78]. The drugs including quinidine D, L-
sotalol, cisapride, and terfenadine used in this study were
associated with QT prolongation and/or torsade de pointes
in humans. Furthermore, drugs such as ketoconazole and
v e r a p a m i lw e r ei n c l u d e da sn e g a t i v ec o n t r o l st od e m o n s t r a t e
speciﬁcity [41]. A detailed dose-response analysis in which
expected eﬀects on QT interval overlapped with prolonged
ﬁeld potential duration demonstrated a good starting point,
but to obtain a higher level of conﬁdence in this system
and to gain industry acceptance, a larger collection of drugs
n e e d st ob ee v a l u a t e d ,a n dt h ec e l l sh a v et ob ep r o d u c e d
under standard operating procedures (SOPs) governed by
an industry standard quality assurance and quality control
system. Alternatively, for the comparison of the drug eﬀects,
t w or e c e n ts t u d i e s[ 79, 80] have demonstrated concordance
between hiPSC-derived cardiomyocytes and conventional,
well-validated, rabbit and canine ex vivo Purkinje ﬁber mod-
els,whicharecommonlyusedasfollow-upassays.Thetrans-
membrane action potential of the ESC- and iPSC-derived
cardiomyocytes has been studied using microelectrodes [80].
The drug-induced arrhythmic events were assessed by using
reverseusedependence,triangulationoftheactionpotential,
and short-term variability of repolarization parameters. The
resultssuggestthattherabbitPurkinjeﬁbersandventricular-
like ESC- and iPSC-derived cardiomyocytes responded in
a similar way with regard to the incidence of early after-
depolarization, increased triangulation, and short-term vari-
ability of repolarization in response to the human ether-a-





and canine Purkinje ﬁbers [79]. Additionally, these cardi-
omyocytesresultedinreducedcompoundconsumption,cost
and time savings compared to the conventional Purkinje
ﬁber assays. The study also reports that these cardiomyocytes
are good detectors of proarrhythmic events and that soon
after depolarization were induced by the reference com-
pounds terfenadine, sotalol, cisapride, and E-4031. It is
known that the compounds that do not interfere with ion
channel functionality can also cause cardiotoxic insults. The
ESC- and iPSC-derived cardiomyocytes are considered to
be well suited to study the eﬀects of compounds which do
not interfere with the ion channel functions but still cause
cardiotoxicity, an eﬀect that cannot be revealed by using
the conventional cell line and receptor overexpression-based
approaches [41].
The ESC- and iPSC-derived cardiomyocytes have recent-
ly been used to study doxorubicin-triggered toxicity [81].
Two clinically decisive biomarkers of cardiac damage that are
sensitive indicators for doxorubicin-induced toxicity were
studied.TheESC-andiPSC-derivedcardiomyocytesreleased
detectable levels of cardiac troponin T and fatty acid-binding
protein 3 in a dose-dependent manner after doxorubicin
induction [82]. Based on the availability of very sensitive and
rapid analytical tools for these biomarkers, the assay lends
itself well to miniaturization and high-throughput formats.
This strategy demonstrates that molecular mechanisms of
cardiotoxicity after drug treatment can be studied.
8. FutureChallenges and Perspectives
One of the important tasks in using ESCs and iPSCs for drug
discovery and toxicity testing is producing large amount of
cells with low heterogeneity that behave in a consistent way.
The robotic and suspension culture methods for ESCs [83,
84]provideanextensivelyevaluatedandstandardizedsystem
for ESC culture. Although derivation of iPSCs is considered
as interesting and superior model system for the develop-
ment of drug discovery and toxicity testing model system,6 Stem Cells International
several obstacles related to the reprogramming procedure
have to be overcome. To increase the yield of reprogrammed
cells, the choice of cells to be reprogrammed is of particular
importance, given the variable reprogrammability of the
diﬀerent cell types [24, 85–87] (Tat et al. [20]). Furthermore
thechoiceofreprogrammingfactorsandgenedeliverymeth-
ods will constitute a cornerstone for each and every drug dis-
covery or toxicity testing application.
The next challenge would be to optimize the protocols
for the diﬀerentiation of ESCs and iPSCs into neuronal and
cardiac lineages, though several protocols have been used to
produce functional neurons and cardiomyocytes from the
ESCs and iPSCs, albeit with varying eﬃciency. Understand-
ing the diﬀerent signaling pathways and factors responsible
for cardiac and neuronal diﬀerentiation of these cells would
help to improve the diﬀerentiation protocols. Development
of more homogenous cell phenotypes after diﬀerentiation
is a necessity for the development of reliable and well-
standardized model system for drug discovery and toxicity
testing. Moreover, production of more mature cell types
from pluripotent stem cells can be beneﬁcial for use as a
model system for adult human organs in pharmacological
and toxicological studies. Culture of the diﬀerentiated neu-
rons and cardiomyocytes may help to produce more appro-
priate cell types for testing pharmacological compounds.
In conclusion, the use of ESC- and iPSC-derived neurons
and cardiomyocytes for drug discovery and toxicity testing
constitute an extremely promising tool when more sophisti-
cated, eﬃcient, and reproducible methods of diﬀerentiation
and for scaling up are be achieved. The early “proof-of-
concept” examples presented in this paper highlights the
trend and the potential of the approach; however the current
industrial and medical practice is still based on the properly
validated “old” technologies. Further major eﬀorts and com-
mitment will be necessary to fulﬁll the expectations towards
pluripotent stem cell-based systems—international eﬀorts
including the recent European Union 7th Framework Pro-
gramme “Innovative Medicine Initiative” calls for human
iPSC-based drug and toxicity testing systems hold good
promise to ﬁnance and stimulate such developments.
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